Climb Bio (CLYM) Cash from Operations (2020 - 2026)
Climb Bio's (CLYM) quarterly Cash from Operations came in at 14379000.0 in Q1 2026, up 6.84% YoY from 13459002.12 in Q1 2025, and up 8.03% on a QoQ basis from 15635000.0 in Q4 2025.
Climb Bio (CLYM) Cash from Operations (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 7 years of Cash from Operations data on file, last reported at 14379000.0 in Q1 2026.
- Quarterly Cash from Operations rose 6.84% year-over-year to 14379000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 53301000.0 (down 82.68% YoY) and the FY2025 annual result came in at 54356000.0, down 249.29% from the prior year.
- Cash from Operations climbed to 14379000.0 in Q1 2026, from 15635000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 3490000.0 in Q3 2023 to a low of 15635000.0 in Q4 2025.
- A 5-year average of 8368529.41 and a median of 8449000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations jumped 183.59% — and 2025, when it tumbled 1571.36%.
- Tracing CLYM's Cash from Operations over 5 years: stood at 8449000.0 in 2022, then jumped by 88.79% to 947000.0 in 2023, then sank by 483.0% to 5521000.0 in 2024, then tumbled by 183.19% to 15635000.0 in 2025, then increased by 8.03% to 14379000.0 in 2026.
- The last three Cash from Operations figures came in at 14379000.0 (Q1 2026), 15635000.0 (Q4 2025), and 12139000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | -10.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.55 Mn |
| Jun 30, 2026 | -10.55 Mn |
| Mar 31, 2026 | -14.38 Mn |
| Mar 31, 2026 | -14.38 Mn |
| Dec 31, 2025 | -15.64 Mn |
| Dec 31, 2025 | -15.64 Mn |
| Sep 30, 2025 | -12.14 Mn |
| Sep 30, 2025 | -12.14 Mn |
| Jun 30, 2025 | -11.15 Mn |
| Jun 30, 2025 | -11.15 Mn |
| Mar 31, 2025 | -15.43 Mn |
| Mar 31, 2025 | -15.43 Mn |
| Dec 31, 2024 | -5.52 Mn |
| Dec 31, 2024 | -5.52 Mn |
| Sep 30, 2024 | -7.56 Mn |
| Sep 30, 2024 | -7.56 Mn |
| Jun 30, 2024 | -667,000.00 |
| Jun 30, 2024 | -667,000.00 |
| Mar 31, 2024 | -1.82 Mn |
| Mar 31, 2024 | -1.82 Mn |